TABLE 1

Distribution of characteristics at baseline and during follow-up to the time of retinopathy progression or the last visit during the study

ConventionalIntensiveP
n729711
CohortNS
    Primary prevention378 (51.9)348 (48.9)
    Secondary intervention351 (48.1)363 (51.1)
Retinopathy level (secondary cohort only) (%)0.01
    Level 20 (microaneurysms only)203 (57.8)249 (68.6)
    Level 30 (mild NPDR)110 (31.3)82 (22.6)
    Level 40 (moderate NPDR)38 (10.8)32 (8.8)
Phase of entry (%)NS
    2: feasibility (1983–1984)132 (18.1)146 (20.5)
    3: full scale (1985–1989)597 (81.9)565 (79.5)
Age (years)26.5 ± 7.127.1 ± 7.1NS
Caucasian race703 (96.4)686 (96.6)NS
Male394 (54.0)366 (51.5)NS
Duration of type 1 diabetes (years)
    Primary cohort2.6 ± 1.42.6 ± 1.4NS
    Secondary cohort8.6 ± 3.78.9 ± 3.8NS
A1C (%)
    Eligibility screening9.1 ± 1.69.1 ± 1.6NS
    During follow-up9.1 ± 1.37.2 ± 0.9<0.001
    Categories (%)
<6.57 (1.0)136 (19.1)<0.001
6.5–7.561 (8.4)357 (50.2)<0.001
7.5–8.5171 (23.5)163 (22.9)NS
8.5–9.5229 (31.4)34 (4.8)<0.001
≥9.5261 (35.8)21 (3.0)<0.001
MBG (mmol/l)
    Baseline12.8 ± 4.413.0 ± 4.60.60
    During follow-up12.9 ± 2.78.6 ± 1.6<0.001
Duration of treatment (years)6.4 ± 1.66.5 ± 1.6NS
  • Data are n (%) or means ± SE. NPDR, nonproliferative diabetic retinopathy.